These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31050887)

  • 1. Direct Measurement of Amorphous Solubility.
    Štukelj J; Svanbäck S; Agopov M; Löbmann K; Strachan CJ; Rades T; Yliruusi J
    Anal Chem; 2019 Jun; 91(11):7411-7417. PubMed ID: 31050887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the amorphous "solubility" of a group of diverse drugs using new experimental and theoretical approaches.
    Almeida e Sousa L; Reutzel-Edens SM; Stephenson GA; Taylor LS
    Mol Pharm; 2015 Feb; 12(2):484-95. PubMed ID: 25495614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2011 Oct; 100(10):4349-56. PubMed ID: 21630280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Effects of Supersaturation Rates and Doses on the Kinetic-Solubility Profiles of Amorphous Solid Dispersions Based on Water-Insoluble Poly(2-hydroxyethyl methacrylate) Hydrogels.
    Schver GCRM; Lee PI
    Mol Pharm; 2018 May; 15(5):2017-2026. PubMed ID: 29601723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of supersaturation of amorphous pharmaceuticals: nonlinear rate of supersaturation generation regulated by matrix diffusion.
    Sun DD; Lee PI
    Mol Pharm; 2015 Apr; 12(4):1203-15. PubMed ID: 25775257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Image-based dissolution analysis for tracking the surface stability of amorphous powders.
    Štukelj J; Agopov M; Yliruusi J; Strachan CJ; Svanbäck S
    ADMET DMPK; 2020; 8(4):401-409. PubMed ID: 35300194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the true solubility advantage for amorphous pharmaceuticals?
    Hancock BC; Parks M
    Pharm Res; 2000 Apr; 17(4):397-404. PubMed ID: 10870982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
    Baghel S; Cathcart H; O'Reilly NJ
    J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Technologies for Amorphization of Poorly Water-Soluble Drugs.
    Kim DH; Kim YW; Tin YY; Soe MT; Ko BH; Park SJ; Lee JW
    Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mathematical model to analyze the dissolution behavior of metastable crystals or amorphous drug accompanied with a solid-liquid interface reaction.
    Hirai D; Iwao Y; Kimura SI; Noguchi S; Itai S
    Int J Pharm; 2017 Apr; 522(1-2):58-65. PubMed ID: 28235625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trade-off between solubility enhancement and physical stability upon simultaneous amorphization and nanonization of curcumin in comparison to amorphization alone.
    Wong JJL; Yu H; Lim LM; Hadinoto K
    Eur J Pharm Sci; 2018 Mar; 114():356-363. PubMed ID: 29309874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting the Solubility Advantage of Amorphous Pharmaceuticals: A Novel Thermodynamic Approach.
    Paus R; Ji Y; Vahle L; Sadowski G
    Mol Pharm; 2015 Aug; 12(8):2823-33. PubMed ID: 26107071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pH-Dependent Liquid-Liquid Phase Separation of Highly Supersaturated Solutions of Weakly Basic Drugs.
    Indulkar AS; Box KJ; Taylor R; Ruiz R; Taylor LS
    Mol Pharm; 2015 Jul; 12(7):2365-77. PubMed ID: 25984769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2010 Mar; 99(3):1254-64. PubMed ID: 19697391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Extent of Supersaturation on the Evolution of Kinetic Solubility Profiles.
    Han YR; Lee PI
    Mol Pharm; 2017 Jan; 14(1):206-220. PubMed ID: 28043130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers.
    Sun DD; Lee PI
    J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Drug Physicochemical Properties on Lipolysis-Triggered Drug Supersaturation and Precipitation from Lipid-Based Formulations.
    Alskär LC; Keemink J; Johannesson J; Porter CJH; Bergström CAS
    Mol Pharm; 2018 Oct; 15(10):4733-4744. PubMed ID: 30142268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
    Baghel S; Cathcart H; O'Reilly NJ
    Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is there a correlation between the glass forming ability of a drug and its supersaturation propensity?
    Blaabjerg LI; Lindenberg E; Löbmann K; Grohganz H; Rades T
    Int J Pharm; 2018 Mar; 538(1-2):243-249. PubMed ID: 29341914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Accuracy of Amorphous Solubility Advantage Calculation by Comparison with Experimental Solubility Measurement in Buffer and Biorelevant Media.
    Zhang W; Haser A; Hou HH; Nagapudi K
    Mol Pharm; 2018 Apr; 15(4):1714-1723. PubMed ID: 29522344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.